Editas Medicine Inc (EDIT)
3.125
+0.24
(+8.51%)
USD |
NASDAQ |
Nov 05, 14:48
Editas Medicine Net Income (Annual): -153.22M for Dec. 31, 2023
Net Income (Annual) Chart
Historical Net Income (Annual) Data
Date | Value |
---|---|
December 31, 2023 | -153.22M |
December 31, 2022 | -220.43M |
December 31, 2021 | -192.50M |
December 31, 2020 | -115.98M |
December 31, 2019 | -133.75M |
Date | Value |
---|---|
December 31, 2018 | -109.95M |
December 31, 2017 | -120.32M |
December 31, 2016 | -97.18M |
December 31, 2015 | -72.90M |
December 31, 2014 | -13.68M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Annual) Range, Past 5 Years
-220.43M
Minimum
2022
-115.98M
Maximum
2020
-163.18M
Average
-153.22M
Median
2023
Net Income (Annual) Benchmarks
EyePoint Pharmaceuticals Inc | -70.80M |
Cassava Sciences Inc | -97.22M |
Regeneron Pharmaceuticals Inc | 3.954B |
Vertex Pharmaceuticals Inc | 3.620B |
Adverum Biotechnologies Inc | -117.16M |